Paolo Goffredo1, Alan F Utria1, Anna C Beck1, Yun Shin Chun2, James R Howe1, Ronald J Weigel1, Jean-Nicolas Vauthey2, Imran Hassan3. 1. Department of Surgery, University of Iowa Hospitals & Clinics, 200 Hawkins Drive, 1516 JCP, Iowa City, IA, 52242, USA. 2. Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA. 3. Department of Surgery, University of Iowa Hospitals & Clinics, 200 Hawkins Drive, 1516 JCP, Iowa City, IA, 52242, USA. imran-hassan@uiowa.edu.
Abstract
BACKGROUND: m-KRAS has been recently reported to be a significant prognostic factor in patients undergoing resection of colorectal liver metastases. This is due to the lack of response to monoclonal epithelial growth factor receptor antibodies, and potentially as a result of a more aggressive tumor biology. METHODS: The National Cancer Database was queried to identify patients with known KRAS status presenting with colorectal cancer and liver metastases who underwent resection of the primary tumor and metastatic disease between 2010 and 2015. RESULTS: A total of 2655 patients were identified of which 1116 (42%) had m-KRAS. Tumor size, lymph node involvement rates, and margin status of the primary tumor were similar between patients with m-KRAS and wild-type KRAS (wt-KRAS). In the multivariable analysis, African-American race and right-sided colon cancers were independently associated with m-KRAS (both p < 0.001). m-KRAS patients had a significantly lower overall survival (OS) than those with wt-KRAS, with a 3- and 5-year OS of 51 vs. 64% and 31 vs. 42%, respectively (p < 0.001). After adjustment for available prognostic confounders, factors independently associated with worse OS were increasing age, receipt of monoagent chemotherapy, tumor size, positive lymph node, and resection margin status of the primary tumor, right-sided cancers, and m-KRAS. CONCLUSIONS: m-KRAS is associated with worse OS in patients presenting with colorectal cancer and liver metastases undergoing resection of the primary tumor and metastatic disease. Right-sided lesions and African-American race were associated with m-KRAS. However, while right-sided remained an independent prognostic factor for OS, race did not.
BACKGROUND: m-KRAS has been recently reported to be a significant prognostic factor in patients undergoing resection of colorectal liver metastases. This is due to the lack of response to monoclonal epithelial growth factor receptor antibodies, and potentially as a result of a more aggressive tumor biology. METHODS: The National Cancer Database was queried to identify patients with known KRAS status presenting with colorectal cancer and liver metastases who underwent resection of the primary tumor and metastatic disease between 2010 and 2015. RESULTS: A total of 2655 patients were identified of which 1116 (42%) had m-KRAS. Tumor size, lymph node involvement rates, and margin status of the primary tumor were similar between patients with m-KRAS and wild-type KRAS (wt-KRAS). In the multivariable analysis, African-American race and right-sided colon cancers were independently associated with m-KRAS (both p < 0.001). m-KRASpatients had a significantly lower overall survival (OS) than those with wt-KRAS, with a 3- and 5-year OS of 51 vs. 64% and 31 vs. 42%, respectively (p < 0.001). After adjustment for available prognostic confounders, factors independently associated with worse OS were increasing age, receipt of monoagent chemotherapy, tumor size, positive lymph node, and resection margin status of the primary tumor, right-sided cancers, and m-KRAS. CONCLUSIONS: m-KRAS is associated with worse OS in patients presenting with colorectal cancer and liver metastases undergoing resection of the primary tumor and metastatic disease. Right-sided lesions and African-American race were associated with m-KRAS. However, while right-sided remained an independent prognostic factor for OS, race did not.
Authors: Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Julien Taieb; Hampig Raphael Kourie; Jean-François Emile; Karine Le Malicot; Ralyath Balogoun; Josep Tabernero; Enrico Mini; Gunnar Folprecht; Jean-Luc Van Laethem; Claire Mulot; Olivier Bouché; Thomas Aparicio; Pierre Michel; Josef Thaler; John Bridgewater; Eric Van Cutsem; Géraldine Perkins; Come Lepage; Ramon Salazar; Pierre Laurent-Puig Journal: JAMA Oncol Date: 2018-07-12 Impact factor: 31.777
Authors: David Lok Hang Chan; Eva Segelov; Rachel Sh Wong; Annabel Smith; Rebecca A Herbertson; Bob T Li; Niall Tebbutt; Timothy Price; Nick Pavlakis Journal: Cochrane Database Syst Rev Date: 2017-06-27
Authors: Dominik D Alexander; John Waterbor; Timothy Hughes; Ellen Funkhouser; William Grizzle; Upender Manne Journal: Cancer Biomark Date: 2007 Impact factor: 4.388
Authors: Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2022-07-27 Impact factor: 4.339
Authors: Florian E Buisman; Daniele Giardiello; Nancy E Kemeny; Ewout W Steyerberg; Diederik J Höppener; Boris Galjart; Pieter M H Nierop; Vinod P Balachandran; Andrea Cercek; Jeffrey A Drebin; Mithat Gönen; William R Jarnagin; T P Kingham; Peter B Vermeulen; Alice C Wei; Dirk J Grünhagen; Cornelis Verhoef; Micheal I D'Angelica; Bas Groot Koerkamp Journal: Eur J Cancer Date: 2022-04-14 Impact factor: 10.002
Authors: Nelleke P M Brouwer; Dave E W van der Kruijssen; Niek Hugen; Ignace H J T de Hingh; Iris D Nagtegaal; Rob H A Verhoeven; Miriam Koopman; Johannes H W de Wilt Journal: Ann Surg Oncol Date: 2019-12-02 Impact factor: 5.344
Authors: Raja R Narayan; Victoria G Aveson; Joanne F Chou; Henry S Walch; Francisco Sanchez-Vega; Gustavo Dos Santos Fernandes; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; Andrea Cercek; Mithat Gönen; Nikolaus Schultz; T Peter Kingham Journal: J Surg Oncol Date: 2022-01-23 Impact factor: 2.885
Authors: Sébastien Tabariès; Matthew G Annis; Anthoula Lazaris; Stephanie K Petrillo; Jennifer Huxham; Amri Abdellatif; Vincent Palmieri; Jaclyn Chabot; Radia M Johnson; Steven Van Laere; Cornelis Verhoef; Yasmina Hachem; Sara Yumeen; Nicholas Meti; Atilla Omeroglu; Gulbeyaz Altinel; Zu-Hua Gao; Alan S L Yu; Dirk J Grünhagen; Peter Vermeulen; Peter Metrakos; Peter M Siegel Journal: Commun Biol Date: 2021-06-02